Table 5.

Adjuvant radiotherapy received (within 3 months after surgery), nodes removed, nodal status, and external-beam radiotherapy (EBRT) received in node-positive patients by risk group defined according to ASTEC radiotherapy eligibility

		Standard surgery (N=683)*	Lymphadenectomy (N=686)*
Low-risk early-stage endometrial cancer
Total		330 (49%)	282 (42%)
Radiotherapy received
	Yes	22 (7%)	24 (9%)
	No	305 (93%)	257 (91%)
	Unknown	3	1
	External beam +/− brachytherapy	12 (4%)	9 (3%)
	Brachytherapy only	10 (3%)	15 (5%)
Nodes removed
	Yes	8 (2%)	255 (92%)
	No	314 (98%)	22 (8%)
	Unknown	8	5
Median number of nodes (range)		2 (1–3)	12 (1–59)
Nodal involvement
	Yes (received EBRT)	1 (1)	6 (2)
	No	7	249
Intermediate-risk and high-risk early-stage endometrial cancer
Total		243 (36%)	264 (39%)
Radiotherapy received
	Yes	137 (56%)	138 (53%)
	No	106 (44%)	124 (47%)
	Unknown	0	2
	External beam +/− brachytherapy	102 (42%)	98 (37%)
	Brachytherapy only	35 (14%)	40 (15%)
Nodes removed
	Yes	14 (6%)	244 (93%)
	No	226 (94%)	17 (7%)
	Unknown	3	3
Median number of nodes (range)		1 (1–16)	12 (1–51)
Nodal involvement
	Yes (received EBRT)	4 (1)	21 (12)
	No	10	233
Advanced endometrial cancer
Total		103 (15%)	124 (19%)
Radiotherapy received
	Yes	62 (61%)	64 (53%)
	No	40 (39%)	56 (47%)
	Unknown	1	4
	External beam +/− brachytherapy	55 (54%)	55 (46%)
	Brachytherapy only	7 (7%)	8 (7%)
Nodes removed
	Yes	10 (10%)	103 (85%)
	No	91 (90%)	18 (15%)
	Unknown	2	3
Median number of nodes		2 (1–6)	13 (1–38)
Nodal involvement
	Yes (received EBRT)	4 (0)	25 (8)
	No	6	78
Unknown, unable to classify risk group
Total		7	16

^*Excludes patients whose pathology details did not confirm endometrial cancer.